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A b s t r a c t  
Solid dispersion is a unique and promising approach for improving the oral absorption and oral 
bioavailability of BCS class II drugs. Modified gum karaya a recently developed excipient was 
evaluated as a carrier for solubility and dissolution enhancement of poorly water soluble drug 
atorvastatin calcium. Physical mixtures along with solid dispersions of drug and polymer was  
prepared using three methods kneading, solvent evaporation and solvent wetting method in 5 
different ratios (1:1,1:3,1:5,1:7,1:9). Among the three methods used atorvastatin calcium solid 
dispersions prepared by kneading method in 1:3 ratio showed most promising results in terms of  
percent yield, percent drug content, solubility of solid dispersions in phosphate buffer pH 6.8, XRD, 
DSC, SEM and In vitro release studies. These solid dispersions were selected to prepare tablets 
using Ac-di-sol as superdisintegrant (T1, T2, T3, T4 and T5). Tablets were characterized for 
hardness, friability, disintegration time, percent drug content, drug release studies and stability 
studies. Tablets T5 showed highest dissolution rate and best dissolution efficiency at (DE30) and 
(DE120) minutes. Release data of T5 tablet was subjected to various release kinetics models to 
know the type and order of drug release. Order was found to be Korsemeyer–Peppas>Hixson–
Crowell cube root law >zero-order >first-order >Higuchi. The similarity factor was calculated for 
comparison of the dissolution profile before and after stability studies. The f2 value was found to be 
more than 50 (~ 90.9) thereby indicating a close similarity between both the dissolution profiles. In 
vivo studies was conducted on healthy albino rats and formulation given by oral route showed that at 
the end of 14 days solid dispersion 1:3 performed better than pure atorvastatin calcium in reducing 
total cholesterol and TG level and increasing HDL- cholesterol levels. 
Keywords: Solid dispersion, solubility, dissolution, atorvastatin calcium, gum karaya, modified gum 
karaya, kneading, co-grinding, solvent evaporation, amorphous, crystalline. 
 
 
 
Introduction 
Oral drug delivery is the simplest and easiest way of administrating 
drugs because of the greater stability, accurate dosage form and 
easy production [1]. A number of newly synthesized chemical 
molecules suffer from low aqueous solubility and dissolution 
problems resulting in low bioavailability. Hence, two areas of 
pharmaceutical research that focus on improving the oral 
bioavailability of active agents include:  
1. Enhancing solubility and dissolution rate of poorly water soluble 
drugs. 
2. Enhancing permeability of poorly permeable drugs. 
 Many approaches such as salt formation, solubilization and 
particle size reduction have been commonly used to increase  
 
 
dissolution rate and thereby oral absorption and bioavailability of 
various drugs. However all these technologies have some potential 
limitations therefore solid dispersion technologies are one of the 
promising approach for improving oral absorption and 
bioavailability of BCS Class II drugs.[2] In the last few years, the 
use of semi-synthetic hydrophilic polymers used as carriers to 
enhance the dissolution rate and bioavailability of poorly water 
soluble drugs. But many of these polymers also limit their 
application as carriers for dissolution enhancement by their high 
viscosity and toughness. Hence development of carriers with high 
swelling and low viscosity may offer better alternative to overcome 
this problem. The usage of natural polymers as drug carriers is on 
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increasing side because of their low cost, biocompatibility and 
biodegradability. [3] 
Gum karaya (GK) is a natural exudate of Sterculia urens, a tree 
native to India belongs to family ‘Sterculiaceae’. It is widely used in 
food industry as it is approved food additive. The wider applications 
of gum karaya is due to its unique features such as high swelling 
and water retention capacity, high viscosity properties, inherent 
nature of antimicrobial activity and abundant availability. Gum 
karaya also acts as fat replacer. [4] It is also evidenced from the 
literature that the gum karaya was used as a laxative due to its 
high swelling ability and formation of discontinuous mucilage. Our 
research reported that the preparation of modified form of gum 
karaya (MGK) and its swelling capacity are beneficial properties 
which overcome the processing and handling problems occurred 
during the preparation of solid mixtures, the present investigation 
aimed to study the influence of MGK on dissolution rate of poorly 
water soluble drug. The drug selected for the evaluation of MGK as 
carrier for solubility and dissolution enhancement is atorvastatin 
calcium as a synthetic lipid lowering agent, is an inhibitor of 3-
hydroxy-3-methyl glutaryl –coenzyme A (HMG CoA) reducatase 
which catalyzes the conversion of HMG-CoA to mevalonate which 
is a rate limiting step in cholesterol biosynthesis. Atorvastain 
calcium is insoluble in aqueous solution of pH- 4 and below, it is 
very slightly soluble in water and pH-7.4 of phosphate buffer. The 
intestinal permeability of atorvastatin calcium is high at the 
physiologically relevant intestinal pH. Hence it is reported that the 
absolute bioavailability of atorvastatin calcium is 12 %. [5]. 
In this study, the influence of concentration of gum and the method 
of preparation of solid dispersions on the dissolution rate was also 
studied. Apparent solubility, in vitro dissolution study, infrared 
spectroscopy, differential scanning calorimetry (DSC), and X- ray 
diffraction (XRD) study were used to explain the phenomenon. 
Release data was subjected to various release kinetics models to 
know the type and order of drug release. The similarity factor was 
calculated for comparison of the dissolution profile before and after 
stability studies. In vivo studies were conducted on healthy albino 
rats to know decrease in total cholesterol level. [6] 
Materials and methods 
Atorvastatin calcium was a gift sample from Cadila Healthcare 
(Ankleshwar, India). Rajesh Chemicals Pvt. Ltd., Mumbai gum 
karaya (Grade 1).All other materials were of analytical reagent 
grade. 
Methods 
Preparation of modified gum karaya 
Powdered gum was taken in a porcelain bowl and subjected to 
heating using sand bath for different time periods at different 
temperatures. Hence in the preparation of modified gum karaya, 
samples were heated at 120ºC for 2 hours. The prepared modified 
gum karaya was finally re-sieved (100 mesh) and stored in an air 
tight container at 25ºC [7]. 
Characterization of GK/MGK 
Viscosity measurement 
The viscosity of 1% (w/v) GK/MGK solution was measured 
according to the US Pharmacopoeia (USP) specification, using 
Brookfield DV-E Viscometer. 
Swelling and water retention capacity [6,7] 
Swelling index 
About 1.0 gm of GK powder was accurately weighed and 
transferred to a 100 ml stopper measuring cylinder. The initial 
volume of the powder in measuring cylinder was noted. The 
volume was made up to 100ml mark with distilled water. The 
cylinder was stoppered and was shaken gently and set aside for 24 
h. The volume occupied by the gum sediment was noted after 24 h. 
Swelling capacity of GK/MGK was expressed in terms of swelling 
index as follows. Swelling index (SI) was expressed as a 
percentage and calculated according to the following equation. 
Equation no: - 1 
 
Si=[(xt-xo)/xo]x100 
           
where 
X0 is the initial height of the powder in graduated cylinder 
Xt denotes the height occupied by swollen gum after 24 hrs. 
Hydration capacity 
Weighed quantity of powdered GK/MGK (1.0 g) was taken in the 
15-ml tare centrifuge tube. Then, 10 ml of distilled water was added 
to it and allowed to centrifuge for 10 min at 1,000 rpm. After the 
centrifugation process, the tare centrifuge tube was taken out and 
inverted to remove the supernatant. The decanted tube then 
weighed on digital balance and the hydration capacity was 
calculated using the following equation. 
Equation no:- 2 
HC = Weight of hydrated sample/Weight of dry sample                      
Angle of repose 
The angle of repose was determined by the funnel method.  
Accurately weighed powder was taken in a funnel. The height of a 
funnel was adjusted in such a way that its tip just touches the apex 
of the heap of powder. The powder was allowed to flow through 
funnel freely on to the surface. The diameter of the powder heap 
was measured and angle of repose was calculated using the 
following equation. [8] 
   
Equation no: - 3                               
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where  
H is the height of powder heap 
R is the radius of powder heap [9]  
 
Table 1: Angle of repose as an indication of powder flow properties 
   Angle of repose(º)    Type of flow 
      <25  Excellent 
      25-30 Good 
      30-40  Passable 
       >40  Very poor 
Moisture sorption capacity 
Moisture sorption study was performed using programmable 
environmental test chamber. One gram of powdered GK/MGK was 
taken in a Petri dish of 9 cm in diameter and spread uniformly. 
Then, it was kept in programmable environmental test chamber at 
37±1°C and 100% relative humidity for 2 days. The moisture 
sorption was calculated by recording weight difference of the 
sample before and after exposure to programmable environmental 
test chamber. 
Density 
The loose bulk density (LBD) and tapped bulk density (TBD) of 
GK/MGK powder were determined. Powdered gum (2 gm) was 
poured into calibrated measuring cylinder (10 ml capacity) and 
noted initial volume. Then, the cylinder was allowed to fall under its 
own weight onto the hard surface from the height of 2.5 cm. The 
tapping was then continued until no further change in volume was 
noted. LBD and TBD were calculated using the following equation. 
[8] 
Equation no: - 4 
LBD = Weight of the powder/Volume of the packing                       
Equation no: - 5                                                     
TBD = Weight of the powder/Tapped volume of the packing           
Compressibility 
Compressibility index (Carr’s index) was determined by using the 
following equation: 
Equation no: - 6                                                  
Carr’s index (%) = [(TBD – LBD) x 100] / TBD                                
 
Determination of volatile acid content 
About 1 gm was accurately weighed, transferred to a 700 ml long 
necked flask.100 ml of water and 5 ml orthophosphoric acid was 
added and allowed to stand for 6 h until the gum was completely 
swollen. Then it was boiled for 2 h under a reflux condenser, and 
then steam distilled until 80 ml of the distillate was obtained. The 
distillate was titrated with N/10 sodium hydroxide using 
phenolphthalein as indicator. The procedure was repeated omitting 
the sample. The difference between the two titrations represented 
the amount of alkali required to neutralize the volatile acid. Each ml 
of 0.1 N NaOH = 0.006005 g of C2H4O2 [10]. 
Preparation of sample 
Preparation of physical mixture of atorvastatin calcium 
Physical mixtures of atorvastatin calcium and modified gum karaya 
was obtained by simple blending the drug and carrier in ratios 1:1, 
1:3, 1:5, 1:7, 1:9 with spatula and then passed through a 100 mesh 
screen and then weighed physically.  
Kneading method 
The Atorvastatin calcium and MGK were triturated in1:1, 1:3, 1:5, 
1:7, 1:9 ratios using 1.5 times the amount of 70% v/v of methanol 
to give a thick paste, which was needed for 20 minutes and then 
dried at 40 0C in an oven. The dried mass was then pulverized, 
passed through mesh 30, stored in vacuum desiccators (48 h). The 
prepared solid dispersion was then grounded by using a mortar 
and pestle, sieved through a mesh 100 and stored over a fused 
calcium chloride in a desiccators for further use. When methanol 
alone was used for kneading; the thick paste got dried immediately. 
To avoid drying of the solvent during kneading, methanol was 
previously mixed with water (1:1) and then used for the kneading 
method [11].  
Solvent evaporation method 
To a solution of atorvastatin calcium (200 mg) in methanol (10 ml) 
was added appropriate amount of MGK, earlier dissolved in 
methanol in1:1, 1:3, 1:5, 1:7, 1:9 ratios. This solution was 
continuously stirred using magnetic stirrer and the solvent was 
evaporated and then stored over night in a desiccators. Solid 
dispersion thus obtained was grounded by using a mortar and 
pestle and sieved through a 100 mesh screen. [12].  
Solvent wetting method  
Atorvastatin calcium was dissolved in an appropriate amount of 
methanol to its saturation solubility in1:1, 1:3, 1:5, 1:7, 1:9 ratios. 
The amount of methanol used was 1.5 times the total weight of 
drug and polymer. After complete dissolution of atorvastatin 
calcium, solutions were dropped into MGK. Then, solvent was 
removed at room temperature. The solid dispersions obtained were 
grounded in a mortar and sieved through 100 mesh screen. [13]. 
Characterization of solid dispersions 
Scanning electron microscopy (SEM) 
The SEM images of pure drug, MGK, physical mixture and solid 
dispersions prepared by kneading method was analyzed by 
scanning electron microscope (JSM 6390, JEOl, Peabody MA, 
USA) with 10-kV accelerating voltage. 
Aggarwal et al. International Journal of Drug Delivery 4 (3) 341-365 [2012] 
 
PAGE | 344 | 
 
 
 
X-ray diffraction (XRD) 
Powder XRD patterns of pure drug, MGK, physical mixture and 
solid dispersion prepared by kneading method were recorded using 
diffractograms using Philips PW 1729 X-ray generator (computer 
1710). Diffractograms were run at a scanning speed of 20/mm and 
a chart speed of 20/2 cm per 2θ.  
Differential scanning calorimetry (DSC) analysis 
DSC curves of pure drug, MGK, physical mixture and solid 
dispersion prepared by kneading method were obtained by 
differential scanning calorimeter (DSC 60 Shimazdu, Japan) at a 
heating rate of 10 0C/min from 30 0C to 300 0C in a nitrogen 
atmosphere. 
Determination of percentage yield and drug content  
Drug content was calculated by dissolving solid dispersions 
equivalent to 20 mg of atorvastatin calcium in a suitable quantity of 
methanol (10 ml), filtered using 45 µm whatman filter paper, 
suitably diluted with methanol and analyzed by using UV 
spectrophotometer against methanol as blank. Similarly, the 
percentage yield of each formulation was determined according to 
the recoverable final weight of solid dispersions and the total 
original weight of atorvastatin calcium and carrier used. 
Equation no: - 7 
 
                                                 
 
where, a is the weight of the solid dispersion sifted through a#120 
sieve, b is the weight of atorvastatin calcium taken for solid 
dispersion preparation, and c is the weight of MGK taken for solid 
dispersion preparation[14]. 
Determination of solubility of solid dispersions 
Atorvastatin calcium, physical mixture or solid dispersions 
equivalent to 20 mg were added to 10 ml of phosphate buffer pH 
6.8 in screw capped vials. The vials were capped properly and 
shaken at 37 0C in a temperature controlled water bath for 48 hrs. 
Resultant samples containing undissolved solid dispersions 
suspended in the screw capped vials were filtered through 0.45mm 
filters, suitably diluted with phosphate buffer pH 6.8 and analyzed 
by UV spectrophotometer at 246 nm [14].  
 In vitro drug release studies 
Dissolution rates from different solid dispersions were determined 
in 900ml of pH 6.8 phosphate buffer at 37±0.5°C with a stirrer 
rotation speed of 50 rpm using the USP dissolution test apparatus 
employing type II Paddle type apparatus. A 5-ml aliquot of 
dissolution medium was withdrawn at 5, 10, 20, 30, 45, 60, 90 
and120 mins. The samples were suitably diluted and assayed 
spectrophotometrically at 246 nm. Each dissolution rate test was 
repeated three times. A model independent approach, dissolution 
efficiency (DE) was employed to evaluate the dissolution rate of 
atorvastatin calcium from different solid dispersions. DE is defined 
as the area under the dissolution curve up to the time t,(measured 
using trapezoidal rule) expressed as a percentage of the area of 
the rectangle described by100% dissolution in the same time.DE30 
and DE120 were calculated from the dissolution data and used for 
comparison[15]. 
 
Equation no: - 8  
DE%=fto y.dt / y100.dt *100                                                             
Formulation of blends 
ATV-Ca 2 solid dispersions and excipients like Ac-di-sol, Avicel pH 
102, lactose were co-grounded in pestle mortar (except talc and 
magnesium stearate) and were passed through mesh no. 60. 
Finally talc and magnesium stearate were added and mixed for 5 
minutes [9].  
Characterization of blends 
The quality of tablet, once formulated by rule, is generally dictated 
by the quality of physicochemical properties of blends. There are 
many formulations and process variables involved in mixing step 
and all these can affect the characteristics of blend produced. The 
characterization of mixed blend done for the flow property of 
powder that are bulk density, tapped density, Hausner’s ratio, 
Compressibility index, angle of repose[8,9].  
Bulk density  
Apparent bulk density (ρb) was determined by pouring the blend 
into a graduated cylinder. The bulk volume (Vb) and weight of 
powder (M) was determined. The bulk density was calculated using 
the formula [9] 
Equation no:-9 
 
                                                                                         
Tapped density 
The measuring cylinder containing a known mass of blend was 
tapped 100 times using density apparatus. The minimum volume 
(Vt) occupied in the cylinder and the weight (M) of the blend was 
measured. The tapped density (ρt) was calculated using the 
formula  
Equation no: - 10  
 
t
t V
M
=r
                                                                                    
b
b V
M
=r
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Compressibility index 
The simplest way for measurement of flow of powder is its 
compressibility, an indication of the ease with which a material can 
be induced to flow is given by compressibility index (I) which is 
calculated as follows. 
Equation no: - 11 
 
100´-=
t
btI
r
rr
                                                   
Where, ρt = Tapped density 
            ρb = Bulk density 
 
Table 2:  Compressibility index as an indication of powder flow 
properties 
 
Carr’s index Type of flow 
15.0-21 Excellent 
12.0-16 Good 
18-21 Fair to passable 
23-35 Poor 
33-38 Very poor 
>40 Extremely poor 
Hausner Ratio 
Hausner ratio (HR) is an indirect index of ease of powder flow. It is 
calculated by the following formula. 
Equation no:-12 
b
tHr
r
r
=                                                       
  
Where, ρt is tapped density and ρb is bulk density. 
Lower Hausner ratio (< 1.25) indicates better flow properties than 
higher ones  
(> 1.25). 
Angle of repose 
Angle of repose was determined using funnel method. The blend 
was poured through a funnel that can be raised vertically until a 
specified cone height (h) was obtained. Radius of the heap (r) was 
measured and angle of repose (θ) was calculated using the 
formula. 
Equation no:-13      
r
h
=qtan
              ; 
÷
ø
ö
ç
è
æ= -
r
h1tanq
                  
           
Where, θ is angle of repose; h is height of cone; r is radius of cone 
 
 
 
Table 3: Angle of repose as an indication of powder flow properties 
Angle of repose Type of flow 
<25 Excellent 
25-40 Good 
  30-40 Passable 
>40 Very poor 
 Formulation of atorvastatin calcium solid dispersion 
tablets 
Atorvastatin calcium solid dispersion tablets of ATV-Ca 2 
formulation were prepared by direct compression method using 
single punch machine (Cadmach, Ahemadabad) 9mm concave 
punch. 20 mg equivalent solid dispersion was taken for each 
formulation. Tablets were prepared with or without using Ac-di-sol 
as superdisintegrant. The concentration of superdisintegrant varied 
from 2-5 % in tablet formulations. The mixed blend of drug and 
excipients was compressed using a single punch tablet machine to 
produce flat faced tablet weighing 250 mg.  
     Table 4. Composition of atorvastatin calcium solid dispersion 
tablets 
Ingredients T1 T2 T3 T4 T5 
ATV-Ca 2 120 120 120 120 120 
Ac-Di-Sol 0 5 7.5 10 12.5 
Avicel pH 102 90 90 90 90 90 
Lactose 30 25 22.5 20 17.5 
Talc 5 5 5 5 5 
Magnesium 
stearate 
5 5 5 5 5 
Characterization of atorvastatin calcium solid dispersion 
tablets 
After compression of powder, the tablets were evaluated for 
organoleptic characteristics like color, odor, taste, diameter, 
thickness and physical characteristics like hardness, friability, 
content uniformity, disintegration time, and in vitro dissolution 
studies. 
General appearance [6] 
Visual identification and over all ‘elegance’ were performed such as 
color, presence or absence of an odour, taste, surface texture and 
physical flaws. 
Tablet thickness 
Tablet thickness is an important characteristic in reproducing 
appearance and also in counting by suing filling equipment. Some 
filling equipment utilizes the uniform thickness of the tablets as a 
counting mechanism. Ten tablets were taken and their thickness 
was recorded using micrometer. 
Uniformity of weight 
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USP procedure for uniformity of weight was followed, twenty 
tablets were taken and their weight was determined individually 
and collectively on a digital weighing balance. The average weight 
of one tablet was determined from the collective weight. The weight 
variation test would be satisfactory method of determining the drug 
content uniformity. 
 In vitro dissolution test 
In vitro dissolution studies of formulation were carried out using 
USP paddle method at 50 rpm in 900 ml of phosphate buffer (pH 
6.8) as dissolution media, maintained at 37±0.50C. 5 ml of aliquot 
was withdrawn at the specified time intervals, filtered through 
whatmann filter paper and analyzed spectrophotometrically at 246 
nm. An equal volume of fresh medium, which was prewarmed at 
same condition, was replaced into the dissolution media after each 
sampling to maintain the constant volume throughout the test [16]. 
Fitting of various kinetic models 
The mechanisms of dissolution of atorvastatin calcium from various 
preparations of solid dispersions were studied. The data were 
treated to study the best linear fit for the following equations [13].  
a) Zero order               : %R = Kt.                                  
b) First order               : Log % unreleased = Kt/ 2.303 
c) Matrix (Higuchi matrix)  : % R = Kt0.5 
d) Korsmeyer- Peppas equation   :   Amount of drug released at 
time t             
                                                            Amount of drug released at 
time '∞' 
e) Hixson-Crowell equation     :  (% unreleased) 1/3 = Kt 
Where ‘n’ is the diffusion coefficient, which is indicative of transport 
mechanism [17]. 
Stability studies 
The accelerated stability studies of T5 formulation was checked as 
per ICH guidelines at 40 ºC and 75± 5% RH upto 1 month. 
Periodically (initial, 7 days, 14 days, 21 days and 30 days) samples 
were removed and analyzed for physical characterization, 
hardness, drug content, disintegration time and in vitro dissolution 
studies. The similarity factor (f2) was used as a basis to compare 
dissolution profiles. The dissolution profiles are considered to be 
similar when f2 is between 50 and100. The dissolution profiles of 
T5 formulation before and after stability testing were compared 
using a similarity factor (f2) which is calculated from the following 
formula:
 
Where, n is the dissolution time and Rj and Tj are the reference 
and test dissolution values at time t [18, 19]. 
 In vivo studies 
The Hypolipidemic activity of prepared T5 formulation of 
atorvastatin calcium solid dispersion tablets was determined in 
comparison with pure atorvastatin calcium in healthy albino rats 
(Wistar strain) of either sex or weighing between150 and 200g will 
be taken and animals will be divided into 3 groups of 4 animals 
each. General and environmental conditions were strictly 
monitored. Animal handling routines were performed according to 
Good Laboratory Practice. Animals were procured from central 
animal house Bela (Ropar). The research protocol of the animal 
experimentation was approved by CPSCEA the Institutional Animal 
Ethics Committee, Bela (Ropar) India.   Each group daily will 
receive 2 ml of coconut oil orally. Reference and Test groups 
additionally will receive orally aqueous suspensions of pure 
atorvastatin calcium and solid dispersion (equivalent to 10 mg/kg 
body weight) respectively, prepared using 2% w/v gum acacia as a 
suspending agent. Blood samples will be collected under light ether 
anesthesia by retroorbital puncture; initially, after 7 days and after 
14 days. The serum samples will be analyzed for total cholesterol, 
triglycerides (TG) and high density lipoprotein (HDL) cholesterol 
levels by the in vitro diagnostic kit (Transasia- Erba,Sem-
Autolyser,Chem 5X model, India). The statistical analysis for the 
determination of differences in lipid profiles of treatment and control 
groups was done by unpaired t-test and p <0.001was taken as 
significant[20]. 
Results and discussion 
The viscosity of GK is directly proportional to its volatile acetyl 
content. Hence, it is assumed that the removal of volatile acetyl 
content in the gum will reduce the viscosity of gum. Results of 
characterization of the GK and MGK are given in Table 5.7 
respectively. The results indicated that the viscosity of MGK was 
markedly lower when compared to that of GK. It is also found that 
volatile acetyl content of MGK significantly less than that of GK. 
Due to swelling nature of carrier, the extensive surface of the 
carrier is increased during dissolution and dissolution rate of 
deposited drug is markedly enhanced. Water retention capacity of 
the carrier is the amount of water retained in it indicates ability of 
carrier towards hydrophilic nature. 
Table 5: Characterization of gum karaya and modified gum karaya 
Parameters Gum Karaya Modified 
Gum Karaya 
Viscosity (cps) 600 ± 56   250 ±35 
Swelling index (%) 1010.66 ± 
95.84 
888.66 ± 
19.62 
WaterRetentionCapacity(ml)   28.54± 
2.28 
 26.62± 2.96 
Hydration capacity 1.208±0.030 1.092±0.08 
Volatile acid content 14± 2.309 11± 1.00 
Angle of repose(Ө) 36±0.00 35±0.606 
Carr’s Index (%) 18± 0.309 18.34± 
0.425 
  
The solubility of atorvastatin calcium increases with the increase in 
polymer concentration, which shows a linear increase in drug 
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solubility with increased carrier level, with R2 values of 0.995, 
indicating AL type solubility diagram. Solubility data of atorvastatin 
calcium in various concentration of modified gum karaya is shown 
in Table 6 respectively and graph is represented in Figure 1 
respectively.  
 
Table 6: Solubility of atorvastatin calcium in modified gum karaya 
S.No. Concentration of 
MGK (%) 
Solubility(µg/ml) 
1 1 0.010±0.004 
2 2 0.017±0.002 
3 3 0.028±0.002 
4 4 0.038±0.002 
5 5 0.045±0.001 
6 6 0.056±0.004 
7 7 0.069±0.004 
Data are expressed as mean ± S.D. (n=3) 
           
 
 
 
Figure;1 
Solubility data of Atorvastatin calcium, physical mixtures and solid 
dispersions are shown in Table 7 respectively. Solubility of drug 
increased with the increment in ratio of polymer. But the 
solubilising effect of solid dispersions prepared by kneading 
method showed more promising results.       
 
The in vitro release profile of atorvastatin calcium, physical 
mixtures and solid dispersions (prepared by kneading method, 
solvent evaporation method, solvent wetting method) ATV-Ca 1, 
ATV-Ca 2, ATV-Ca 3, ATV-Ca 4, ATV-Ca 5, ATV-Ca 6, ATV-Ca 7, 
ATV-Ca 8, ATV-Ca 9, ATV-Ca 10, ATV-Ca 11, ATV-Ca 12, ATV-
Ca 13, ATV-Ca 14, ATV-Ca 15 is shown in Table 8to 11 and graph 
for the comparison of cumulative percent drug release versus time 
is shown in Figure 2 to 5. In all the cases, 
 
 
Table 7: Solubility data of atorvastatin calcium from physical 
mixtures and 
 solid dispersions in comparison with pure atorvastatin calcium 
 
Formulation Number Solubility(µg/ml) 
Pure drug 0.120 ± 0.002 
ATV-Ca 1 0.240 ± 0.003 
ATV-Ca 2 0.351 ± 0.002 
ATV-Ca 3 0.423 ± 0.002 
ATV-Ca 4 0.470 ± 0.001 
ATV-Ca 5 0.484 ± 0.006 
ATV-Ca 6 0.218 ± 0.001 
ATV-Ca 7 0.321 ± 0.002 
ATV-Ca 8 0.375 ± 0.003 
ATV-Ca 9 0.422 ± 0.003 
ATV-Ca 10 0.482 ± 0.001 
ATV-Ca 11 0.201 ± 0.002 
ATV-Ca 12 0.298 ± 0.004 
ATV-Ca 13 0.354 ± 0.002 
ATV-Ca 14 0.395 ± 0.001 
ATV-Ca 15 0.438 ± 0.001 
PM 1 0.156 ± 0.001 
PM 2 0.171 ± 0.003 
PM 3 0.184 ± 0.002 
PM 4 0.191 ± 0.006 
PM 5 0.199 ± 0.002 
 
cumulative percent release was much greater than pure 
atorvastatin calcium. Hence it is apparent that as the percent of 
carrier is increased, the dissolution rate also increased. Pure 
atorvastatin calcium yielded the slowest percent release due to its 
hydrophobic property causing the powder to float on the surface of 
the dissolution media and prevented its surface to make contact 
with medium for initial time intervals. Hence the enhancement of 
the atorvastatin calcium dissolution rate by solid dispersion 
technique compared with that of the pure drug, could presumably 
be explained by the following factors :1) swelling ability of the 
carrier 2) low viscosity of the carrier 3) a decrease in crystallinity 
y = 103.6x + 0.092
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and size  of the drug crystals in the solid dispersion. 4) Increased 
solubility 5) an improved drug wettability.  
When the mixture comes in contact with water, the polymer 
particles might have hydrated rapidly into polymer solution 
solubilizes the adjacent drug particles and subsequently releases 
the drug into the medium.  
Dissolution efficiency of pure atorvastatin calcium, physical 
mixtures and all solid dispersions at 30 and 120 minutes were 
calculated which is shown in Table 12 respectively. As the 
dissolution time was increased from 30 to 120 minutes, the 
dissolution efficiency was increased in all solid dispersions. Among 
the formulations ATV-Ca 2 has shown maximum dissolution 
efficiency of 24.77% and 44.16 % at thirty minutes (DE30) and one 
twenty minutes (DE120) respectively. Improvement in dissolution 
rate of atorvastatin calcium in solid dispersions compared with pure 
drug might be due to the solubilization effect and wetting ability of 
modified gum karaya on atorvastatin calcium. On the basis of 
results obtained, the method of preparation of solid dispersion also 
influences the rate of dissolution. The reason for higher dissolution 
rate of solid dispersion prepared by kneading method is due to, 
synergistic effect of trituration and solubilization effect of used 
solvent further reduced the crystallinity leading to improvement in 
dissolution rate. Furthermore, kneading results in uniform 
distribution of drug in the polymer crust in a highly dispersed state. 
Thus, Solvent wetting method enhances the dissolution rate of 
atorvastatin calcium due to wetting effect of solvent. It was also 
proved that as the viscosity of carrier decreased, the dissolution 
rate also increased. During the process of dissolution, as soon as 
the drug carrier particles comes in contact with dissolution fluid, 
seeping in of dissolution medium in to the drug carrier particle is 
taking place, which initiated the formation of gel layer of carrier 
around the particle. The diffusion of dissolved drug through the 
gelatinous layer is determining factor in the enhancement of 
dissolution rate. 
SEM images of atorvastatin calcium, modified gum karaya, 
physical mixtures and solid dispersions are shown in Figure 6 to 9 
respectively. It was observed that atorvastatin calcium is present 
as irregular shaped crystals and modified gum karaya as 
multifaceted, slippery surfaced granules. It is clearly visible that in 
ATV-Ca 2 formulation (1:3 solid dispersion prepared by kneading 
method) does not show any crystalline material. The SEM also 
supports data obtained from XRD and DSC. 
The X-ray Diffractograms of pure atorvastatin calcium, modified 
gum karaya, physical mixtures, and solid dispersion is shown in 
Figure 10 to 13 respectively. Hence it is evident from Figure 5.19 
that characteristic diffraction peaks of atorvastatin calcium is at 2Ө 
= 9.12, 9.44, 10.23, 10.54, 11.82, 12.16, 16.97, 19.45, 21.59, 
22.62, 23.22 and 23.68. However modified gum karaya exhibited 
characteristic single peak at 28º with low intensity indicating their 
amorphous nature as shown in Figure 5.20. The XRD of physical 
mixtures of atorvastatin calcium and modified gum karaya and 
atorvastatin calcium 2 solid dispersion show peaks corresponding 
to atorvastatin calcium and also the peaks related to modified gum 
karaya persists respectively. But in Figure 5.22 the atorvastatin 
calcium peaks with reduced peak height and area were observed, 
suggesting reduced crystallinity of atorvastatin calcium in ATV–Ca 
2 formulation prepared by kneading method. 
The DSC runs for atorvastatin calcium, modified gum karaya and 
solid dispersions are shown in Figure 14-16.The DSC curve for 
atorvastatin calcium showed a sharp melting endotherm at 
150ºC.The DSC curve for modified gum karaya exhibited a broad 
endothermic peak owing due to amorphous nature. Further the 
solid dispersion (ATV-Ca 2) showed no endothermic peak 
corresponding to the melting point of atorvastatin calcium indicating 
that drug is dispersed amorphously in modified gum karaya matrix. 
From the above characterization of solid dispersions the ATV-Ca 2 
(solid dispersions of atorvastatin calcium with modified gum karaya 
in ratio 1:3prepared by kneading method) found to be more 
approachable for incorporation in tablets due high saturation 
solubility and higher dissolution efficiency. 
Total five formulations were formulated and designated as T1, T2, 
T3, T4 and T5. 
The characterization of mixed blend was performed for 
determination of mass volume relationship parameters. The 
evaluated parameters are bulk density, tapped density, hausner 
ratio, compressibility index and angle of repose. The bulk density of 
mixed blend varied between 0.564 ± 0.002 to 0.682 ± 0.009 
(g/cm3). The tapped density was found in the range of 0.619±0.004 
to 0.745± 0.001(g/cm3). The hausner ratio was found in range of 
1.116± 0.803 to 1.128± 0.496.The powder blends of all the 
prepared formulations had hausner ratio of less than 1.14 
indicating the good flowability .The compressibility index was found 
in range of 11.496± 0.006 to 12.447±0.014 (%). The 
compressibility –flowability correlation data indicating a good 
flowability of the powder blend. The angle of repose was found to 
be 20.055±0.876 to 24.280±0.446 (º).The angle of repose is below 
than 30º range indicating good to excellent flow properties of blend. 
The results for characterization of blends of solid dispersion tablets 
are shown in Table 13. After compression of blend, the tablets 
were evaluated for their physical properties like color, odour, 
physical, shape and texture) and quality control parameters like 
diameter, thickness, hardness, friability and disintegration time and 
in vitro dissolution studies. All the tablets were grayish in color, flat 
in shape with smooth surface having zero defects. The prepared 
tablets were elegant and have lot to lot tablet uniformity and also 
free from any surface texture problems.  
The thickness of the tablet was found 3.14± 0.02 to 4.31± 
0.03mm.The weight of the prepared tablets was found to be in the 
range of 248 ± 3.0 to 252 ± 6.1 mg. So it was predicted that all the 
tablets exhibited uniform weight with low standard deviation values 
with acceptable variation as per IP. The results are shown in Table 
5.20.The hardness of the prepared tablets varied from 2.3 ± 0.28 to 
3.3± 0.28 (Kg/Cm2). The tablets have satisfactory strength to 
withstand the applied mechanical shocks. 
The friability of all the tablets was found to be less than 1.0% which 
shows the durability of the prepared tablets and resistance to loss 
of weight indicating the tablet’s ability to withstand abrasion in 
handling, packaging and shipment. 
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In the formulation of atorvastatin calcium solid dispersion tablets, 
Ac-di-sol was used as a superdisintegrant. T5 formulation shows 
better disintegration properties when compared to T1 formulation in 
which no superdisintegrant was added. The disintegration time of 
these tablets varied from 6 to 27 minutes (Table 14). 
The drug content of all the tablet formulations was determined 
spectrophotometrically at 246 nm as shown in Table 15. It varied 
from 19.012 ± 0.011 to 20.943 ± 0.034 mg per tablet. Low values 
of standard deviation indicated uniformity of the drug content in the 
prepared tablets.  
The results in vitro drug release of atorvastatin calcium solid 
dispersion tablets indicated  that as the concentration of the 
superdisintegrant (Ac-di–sol) was increased the dissolution rate 
increased and also the drug was released faster. The maximum 
drug release was found in formulation T5 (69.41 %) as shown in 
Table 16. The disintegrant Ac- di- sol shows the faster 
disintegration as its concentration was increased. So the order of 
drug release was found to be in the following order 
T5 > T4 >T3 > T2 > T1 > M 
Dissolution efficiency of all the atorvastatin calcium tablets was 
calculated at 30 to 120 minutes and data is shown in Table 17. 
Among the formulations T5 has shown maximum dissolution 
efficiency of 22.14 at 30 minutes (DE30) and 42.19 at 120 minutes 
(DE120). 
Release data of T5 tablet was subjected for kinetic treatment to 
know the type and order of drug release Table 18 lists the 
regression parameters obtained after fitting various release kinetics 
models to in vitro dissolution data. The goodness of fit for various 
models investigated for binary systems ranks in the order of 
Korsemeyer-Peppas>Hixson–Crowell cube root law >zero-order 
>first-order >Higuchi. The Korsemeyer-Peppas model describes 
drug release kinetics in the most be fitting manner. The value of 
diffusional exponent “n” was obtained from the slopes of the fitted 
Korsemeyer-Peppas model. The solid dispersion tablets tended to 
exhibit Fickian diffusional characteristics, as the corresponding 
values of n were lower than the standard value from declaring 
Fickian release behavior, the results point out the prevalence of 
diffusional mechanistic phenomena. Hence results of various 
kinetic models are shown in Figure 18 to 22 respectively.  
All the formulations showed no significant variation in all the 
parameters under the test period at different conditions i.e.(40ºC 
(75±5 % RH). The results are shown in Table 19 respectively. The 
similarity factor was calculated for comparison of the dissolution 
profile before and after stability studies. The f2 value was found to 
be more than 50 (~ 90.9) thereby indicating a close similarity 
between both the dissolution profiles.  
Hence, the results of the stability studies confirmed that the 
developed formulation is very stable which can be seen in Figure 
23. 
 
 
Table 8: Dissolution profile of pure atorvastatin calcium and solid dispersions prepared by kneading method 
 
 
 Time 
(min) 
              Cumulative Mean  Percent Released ± Standard Deviation 
 
Pure Drug ATV-Ca 1 ATV -Ca2 ATV-Ca 3 ATV –Ca 4 ATV-Ca 5 
 
5    0.32±0.45 10.60±0.50 19.60±0.74 16.39±0.38 18.32±0.34 18.64±0.19 
 
10 4.18±0.12 15.76±0.25 29.91±0.92 18.98±0.26 22.48±0.22 23.84±0.68 
 
20 6.10±0.36 19.63±1.05     35.73±0.58     24.78±0.46 25.43±0.67 26.72±0.58 
 
30 11.90± 0.73 26.72±0.68 40.27±0.66 32.53±0.78 32.86±0.45 33.82±1.07 
 
45 16.09±0.40 32.54±1.34 52.53±0.94 36.42±1.46 42.86±0.50 43.50±0.65 
 
60 20.93 0.80 38.36±0.59 60.30±1.26  49.32±0.83 51.26±0.36 52.55±0.78 
 
90 24.95±0.64 46.76±0.87 66.47±0.54 53.23±0.35 56.46±0.58 58.39±0.33 
 
120 28.49±0.49 48.10±0.60 72.65±0.48 58.43±0.56 62.31±1.28 66.17±0.21 
                              
Data are expressed as mean ± S.D. (n=3) 
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Table 9: Dissolution profile of pure atorvastatin calcium and solid dispersions prepared by solvent evaporation method 
 
Time (min) 
Cumulative Mean  Percent Released ± Standard Deviation 
 
Pure Drug ATV-Ca 6 ATV –Ca7 ATV-Ca 8 ATV–Ca 9 ATV-Ca 10 
 
 
5    0.32±0.45 9.32±0.47 16.39±0.36 12.53±0.91 14.46±0.80 16.39±0.91 
 
10 4.18±0.12 13.83±1.30 26.05±0.28 17.04±0.46 19.62±0.45 20.91±0.60 
 
20 6.10±0.36 20.91±1.26 34.44±0.44 21.56±0.38 25.43±1.50 25.43±0.46 
 
30 11.90±0.73 26.08±0.56 42.83±0.27 29.94±0.94 30.60±0.47 32.53±1.26 
 
45 16.09±0.40 35.75±0.38 52.52±0.75 36.41±0.44 43.27±1.38 43.49±0.65 
 
60 20.93 0.80 40.29±0.22 57.08±0.34 42.88±0.89 50.65±0.87 51.26±1.40 
 
90 24.95±0.64 44.19±0.35 66.14±0.36 51.28±0.62 54.52±0.51 56.46±0.39 
 
120 28.49±0.49 
          
46.81±1.57 70.07±0.52 52.62±0.98 60.35±0.65 64.23±0.41 
Data are expressed as mean ± S.D. (n=3) 
 
Table 10: Dissolution profile release of pure atorvastatin calcium and solid dispersions prepared by solvent wetting method 
 
Time 
(min) 
              Cumulative Mean  Percent Released ± Standard Deviation 
 
Pure Drug ATV-Ca 11 ATV –Ca12 ATV-Ca 13 ATV–Ca 14 ATV-Ca 15 
 
 
5    0.32±0.45 7.39±0.32 15.10±0.68 7.71±1.32 10.92±0.30 12.53±0.36 
 
10 4.18±0.12 11.90±1.48    24.12±0.73 11.96±0.67 13.83±0.29 17.69±0.48 
 
20 6.10±0.36 14.48±0.67 32.50±0.92 16.43±0.89 20.27±0.51 25.92±0.30 
 
30 11.90± 0.73 18.35±1.20 41.54±0.31   20.94 ±0.94 26.72±0.64 35.13±0.27 
 
45 16.09±0.40 23.52±0.49 49.94±0.58 26.75±0.47 35.11±0.30 40.92±0.45 
 
60 20.93 0.80 29.97±0.30 56.43±0.39 31.91±1.43 43.51±0.56 44.82±0.52 
 
90 24.95±0.64 32.58±0.32 65.49±0.20 39.66±0.54    48.05±0.34 50.66±0.41 
 
120 28.49±0.49 43.54±1.70 66.20±0.10 45.49±0.38 52.61±0.64 60.03±0.20 
                                                  
Data are expressed as mean ± S.D. (n=3) 
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Table 11: Dissolution release profile of physical mixtures 
 
 Time (min) 
              Cumulative Mean  Percent Released ± Standard Deviation 
 
Pure Drug PM 1 PM 2 PM 3 PM 4 PM 5 
 
5 
    0.32±0.45 8.03±0.43 10.3±0.59 9.54±0.31 8.35±1.58 9.03±0.59 
10 
 4.18±0.12 9.96±0.37 12.52±0.91 11.4±0.59 10.8±0.43 11.98±0.1.31 
20 
 6.10±0.36 12.52±0.67 15.75±0.48 14.76±0.38 13.82±0.50 15.19±0.92 
30 
 11.90± 0.73 14.71±0.20 18.96±0.31 18.43±0.51 16.93±0.36 17.4±0.30 
45 
 16.09±0.40 17.32±0.19 20.89±0.63 20.00 ±0.32 18.64±0.58 18.72±0.58 
60 
 20.93 0.80 19.28±0.22 23.42±0.34 22.38±1.46 21.21±0.42 22.27±0.41 
90 
 29.95±0.64 22.14±1.82 26.62±0.40 25.52±0.36 23.4±0.18 24.1±0.24 
120 
 34.49±0.49 23.1±0.38 29.17±1.29 27.4±0.91 24.42±1.53 26.36±0.31 
                                           
Data are expressed as mean ± S.D. (n=3) 
Table 12: Determination of dissolution efficiency of solid dispersions 
Formulation Number DE30 % DE120 % 
Pure drug 5.18 18.28 
ATV-Ca 1 13.83 28.97 
ATV-Ca 2 24.77 44.16 
ATV-Ca 3 18.39 34.03 
ATV-Ca 4 19.89 37.12 
ATV-Ca 5 19.90 37.69 
ATV-Ca 6 13.88 27.84 
ATV-Ca 7 24.02 43.03 
ATV-Ca 8 14.63 32.34 
ATV-Ca 8 17.64 36.28 
ATV-Ca 10 18.39 37.69 
ATV-Ca 11 10.13 21.93 
ATV-Ca 12                                       24.02 42.47 
ATV-Ca 13 11.26 24.47 
ATV-Ca 14 13.88 30.37 
ATV-Ca 15 16.89 34.31 
PM 1 9.94 15.32 
PM 2 12.19 18.17 
PM 3 12.80 17.29 
PM 4 10.69 16.25 
PM 5 10.62 16.62 
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Table 13: Characterization of blends 
Formulation 
code 
Bulk density 
(g/cm3) 
Tapped density 
(g/cm3) 
 
 
Hausner 
Ratio 
Compressibility index 
(%) 
 
Angle of 
Repose(°) 
T1 
 0.643±0.005 0.745±0.001 1.120±1.236 12.447±0.014 24.280±0.446 
T2 
 0.578±0.008 0.619±0.004 1.127±0.782 11.496±0.006 24.221±0.728 
T3 
 0.626±0.008 0.727±0.001 1.116±0.803 12.411±0.003 23.405±0.449 
T4 
 0.564±0.002 0.628±0.009 1.122±0.552 12.318±0.006 20.055±0.876 
T5 
 0.682±0.009 0.656±0.011 1.128±0.496 12.224±0.018 23.715±0.336 
 
Table 14: Characterization of atorvastatin calcium solid dispersion tablets 
Formulation code Thickness 
(mm) 
Weight 
uniformity 
(mg) 
 
Hardness 
(Kg/Cm2) 
 
Friability (%) 
 
Disintegration time 
(Minutes) 
 
T1 
 
3.21 ± 0.04 
 
250  ± 2.0 
 
3.3± 0.28 
 
0.44 ± 0.011 
 
27 
 
T2 
 
 3.14± 0.02 
 
252 ± 6.1 
 
3.0 ± 0.11 
 
0.67 ± 0.008 20 
 
T3 
 
3.22 ± 0.06 
 
248 ± 2.0 
 
3.0 ± 0.60 
 
0.52 ± 0.027 15 
 
T4 
 
3.74 ±0.04 249 ± 3.0 
 
3.3 ± 0.15 
 
0.56 ± 0.013 
 
13 
 
T5 
 
4.31± 0.03 
 
250 ± 0.28 
 
2.3 ± 0.28 
 
0.37 ± 0.091 
 
6 
 
 
 
 
Table 15: Drug content of T1-T5 solid dispersion tablets 
Formulation code 
 
Drug content 
(mg per tablet) 
 
Drug content (%) 
 
T1 
 19.91 ± 0.017 99.56 ± 0.24 
T2 
 19.53 ± 0.034 97.65 ± 0.34 
T3 
 20.12 ± 0.041 100.6 ± 0.41 
T4 
 19.42 ± 0.011 97.12 ± 0.11 
T5 
       20.17 ± 0.024  100.85 ± 0.45   
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Table 16: Dissolution profile of atorvastatin calcium from marketed product andsolid dispersion tablets 
 
 Time 
(min) 
              Cumulative Mean  Percent Released ± Standard Deviation 
 
MP 
 
   T1  T2  T3  T4  T5 
 
5 4.17±0.11 9.32±0.48 10.60±0.82 10.92±0.26 15.75±0.23 18.96±0.67 
 
10 6.11± 0.28 10.61±0.63 12.59±0.71 14.47±0.45 18.98±0.35 24.12±0.28 
 
20 10.61±0.24 18.98±1.25 18.99±0.62 24.13±1.45 22.21±1.57 30.58±0.27 
 
30 14.48±0.46 26.72±0.97 28.65±0.53 33.16±0.40 36.38±0.58 39.65±0.58 
 
45 19.00±0.84 32.53±0.81 34.47±0.48 40.27±0.31 38.35±0.46 46.13±0.26 
 
60 20.31 ±0.96 40.28±0.59 42.86±1.34 48.02±0.47 53.82±0.90 56.46±1.35 
 
90 23.54±0.45 46.76±0.64 54.80±0.56 55.79±0.64 59.02±0.27 64.84±0.96 
 
120 24.21±0.54 48.09±0.96 56.47±0.41 62.28±0.82 66.13±0.38 69.41±0.46 
Data are expressed as mean ± S.D. (n=3) 
 
 
 
Table 17: Dissolution efficiency of marketed product and solid 
dispersion tablets 
 
Formulation Number 
 
Dissolution efficiency (%) 
 
DE30 DE120 
 
MP 
 
6.71 13.13 
T1 
 
12.76 28.97 
T2 
 
13.51 33.47 
T3 
 
16.89 35.72 
T4 
 
17.64 38.53 
T5 
 
22.14 42.19 
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Table 18: Fitting of drug release from T5 tablet to various release 
kinetic models 
S. No. Mech. Slope R2 
 
1 Zero order 0.446 
 
0.930 
2 First order 0.003 0.976 
 
3 Higuchi 5.971 0.972 
 
4 Hixson Crowell cube root law 0.026 
 
0.931 
5 Korseyemer - Peppas 
 
0.430 
 
0.991 
Table 19: Evaluation parameters after stability studies 
 
       Parameters 
  
Conditions 40ºC (75±5 % RH) 
 
 
Time Period(days) 
 
 
0 
 
 
7 
 
14 
 
21 
 
30 
Color appearance Grey Grey Grey 
 
Grey Grey 
 
 
Hardness (kg/cm2) 3.0 3.0 
 
3.0 3.0 2.9 
Drug Content (mg) 
 
98.94 
 
98.93 98.93 98.93 98.91 
 
 
 Disintegration Time (s) 
 
10 
 
10 10 10 10 
 
Table 20: Serum lipid profiles of various experimental groups at different time intervals 
S.No. Experimental group Time intervals Total cholesterol 
(mg/dl)* 
Total TG 
(mg/dl)* 
HDL -
cholesterol 
(mg/dl)* 
1. 
 
 
 
Control 
 
 
 
 
 
Initial 
7 days 
14 days 
62.7 ± 3.37 
 
76.8 ± 4.48 
 
91.3 ± 2.95 
72.27 ± 0.18 
 
149 ± 1.92 
 
192 ± 2.28 
22 ± 1.3 
 
34 ± 2.6 
 
39 ± 1.4 
  
2. Reference Initial 
7 days 
14 days 
54.6 ± 2.55 
 
60.2 ± 2.43 
 
57.7 ± 1.51** 
75 ± 2.16 
 
128 ± 0.42 
 
144 ± 3.21** 
 
20 ± 1.56 
 
51 ± 2.34 
 
55 ± 1.85** 
3. Test Initial 
7 days 
14 days 
 
61.23 ± 2.32 
 
   64.3 ± 240 
 
57.8 ± 1.43** 
80.14 ± 1.06 
 
132 ± 2.03 
 
112 ± 1.15** 
 
21 ± 1.67 
 
54 ± 2.45 
 
58 ± 1.50** 
*Mean ± SD, n=6, **p < 0.001 
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Figure: 2: In vitro dissolution profile of cumulative %drug released vs time prepared  by kneading method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 3: In vitro dissolution profile of cumulative %drug released vs time 
prepared by solvent evaporation method 
                                                  
 
Figure 4: In vitro dissolution profile of cumulative %drug released vs time prepared by solvent wetting method 
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Figure: 5: In vitro dissolution profile of cumulative %drug released vs time prepared by physical mixing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Scanning electron photomicrograph of atorvastatin calcium 
 
 
Figure 7: Scanning electron photomicrograph of modified gum karaya 
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Figure 8: Scanning electron photomicrograph of physical mixtures (1:3) of 
atorvastatin calcium and modified gum karaya 
 
     
Figure 9: Scanning electron photomicrograph of ATV-Ca 2 formulation 
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Figure: 10: X-ray diffraction of atorvastatin calcium 
 
 
 
Figure: 11: X-ray diffraction of modified gum karaya 
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Figure 12: X-ray diffraction of physical mixtures (1:3) of atorvastatin calcium and modified gum karaya 
 
 
 
 
 Figure 13: X-ray diffraction of ATV-Ca 2 formulation 
 
 
 
 
 
 
Aggarwal et al. International Journal of Drug Delivery 4 (3) 341-365 [2012] 
 
PAGE | 360 | 
 
 
 
 
Figure 14: DSC thermogram of atorvastatin calcium 
 
 
Figure15: DSC thermogram of modified gum karaya 
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Figure16: DSC thermogram of ATV-Ca 2 solid dispersions 
 
 
Figure 17: Plot of cumulative %drug released vs time of marketed product and solid dispersion tablets   
 
 
 
Figure 18: Zero order release profile of T5 atorvastatin calcium solid dispersion 
tablets 
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Figure 19: First order release profile of T5 atorvastatin calcium solid 
dispersion tablets 
 
 
Figure 20: Higuchi release profile of T5 atorvastatin calcium solid dispersion 
tablets 
 
 
Figure 21: Hixson crowell cube root law release profile of T5 atorvastatin calcium 
solid dispersion tablets formulation 
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Figure 22: Korseyemer- peppas release profile of T5 atorvastatin calcium solid 
dispersion tablets 
 
 
Figure 23: Comparison of dissolution profile before and after stability studies of 
T5 solid dispersion tablets 
 
 
 
Figure 24: Percent change in serum total cholesterol levels of experimental group 
at different time intervals 
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Figure 25: Percent increase in serum TG levels of experimental group 
at different time intervals 
 
 
   Figure 26: Percent increase in serum HDL-cholesterol levels of experimental 
group at different time intervals 
 
Hypolipidemic drugs like atorvastatin calcium (HMG CoA reductase 
inhibitors) are known to elevate total cholesterol and TG level in 
blood. At the same time they cause elevation of the HDL- 
cholesterol levels, which promote the removal of cholesterol from 
peripheral cells and facilitate the delivery back to the liver. This 
pharmacodynamic effect is reported to be dose dependent hence 
was used as a comparison of the in vivo performance of pure 
atorvastatin calcium and solid dispersion 1:3. Administration of 
excess coconut oil, which is a rich source of saturated fatty acids, 
promotes biosynthesis of cholesterol in liver and leads to 
hypercholesterolemia. The serum lipid profiles of all the 
experimental groups at different time intervals are Table 20 and the 
% changes in lipid profiles are plotted in Figure 25 to 26. As 
expected, after7days of treatment with excess coconut oil, control 
group showed significant increase in total cholesterol, TG and 
HDL-cholesterol. Whereas, reference group showed around 
16%decrease in total cholesterol, 21%increase in TG and17% 
increase in HDL-cholesterol. Interestingly, test group in comparison 
to reference presented three-fold decrease in total cholesterol, 
almost similar increase in TG and 1.4-fold increase in HDL-
cholesterol.After14 days of similar treatment, control group showed 
further increase in all the lipid levels. The reference group showed 
slight further decrease in total cholesterol, significant increase in 
TG and negligible increase in HDL-cholesterol. Test group on the 
other hand, presented further two fold decrease in total cholesterol, 
negligible increase in TG and further1.4-fold increase in HDL-
cholesterol in comparison with the reference group. Thus, at the of 
14 days study solid dispersion 1:3 performed better than pure 
atorvastatin calcium  in reducing total cholesterol and TG level and 
increasing HDL- cholesterol levels. This could primarily attribute to 
improved solubility and dissolution associated with amorphization 
of the drug.  
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